Evolus (EOLS) Restructuring Costs (2020 - 2025)
Evolus (EOLS) reported Restructuring Costs of $1.4 million for Q3 2025, down 51.18% quarter-over-quarter from $3.0 million in Q2 2020.
Evolus (EOLS) Restructuring Costs (2020 - 2025) Analysis & Trends
Evolus has reported Restructuring Costs for 2 years, with the latest figure at $1.4 million in Q3 2025.
- For the quarter ending Q3 2025, Restructuring Costs changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (changed N/A YoY), and the FY2025 full-year result was $1.4 million, changed N/A from the prior year.
- Restructuring Costs for Q3 2025 stood at $1.4 million, down from $3.0 million in the prior quarter.
- The five-year high for Restructuring Costs was $1.4 million in Q3 2025, with the low at $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Evolus | 435.45 Mn | 385.65 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2020 | 2.96 Mn |